ArriVent Posts $133.5 Million Loss as Cancer Trial Falls Short
NEWTOWN SQUARE, PA — ArriVent BioPharma Inc. (Nasdaq: AVBP) reported a $133.5 million net loss for the first nine months of 2026, up from $130.8 million a year earlier, as …
ArriVent Posts $133.5 Million Loss as Cancer Trial Falls Short Read More